Astrazeneca is going to start beginning Phase 1/2 clinical trials coronavirus vaccine in Japan, the company said today.
Trials of the vaccine, known as AZD1222, will be held at multiple facilities in Japan, targeting 250 subjects, the company said in a release.
The British company is working with Daiichi Sankyo, JCR Pharma and other partners in Japan to make and distribute the vaccine.
